These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16156296)

  • 21. Rationale for the use of a low molecular weight heparin during hemodialysis with polysulphone membrane in uremic patients.
    Moia M; Graziani G; Tenconi PM; Martinelli I; Ponticelli C
    Ann Ital Med Int; 1997; 12(2):67-71. PubMed ID: 9284597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Filtration of native and glycated beta2-microglobulin by charged and neutral dialysis membranes.
    Randoux C; Gillery P; Georges N; Lavaud S; Chanard J
    Kidney Int; 2001 Oct; 60(4):1571-7. PubMed ID: 11576375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin.
    Fukuda T; Kamisato C; Honda Y; Matsushita T; Kojima T; Furugohri T; Morishima Y; Shibano T
    Thromb Res; 2013 Jun; 131(6):540-6. PubMed ID: 23673387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatocyte growth factor/activin A/follistatin system activation during hemodialysis with different low molecular weight heparins.
    Rydzewska-Rosołowska A; Borawski J; Myśliwiec M
    Ren Fail; 2009; 31(9):791-7. PubMed ID: 19925286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of single dose low-molecular-weight heparin in long hemodialysis.
    Lai KN; Ho K; Li M; Szeto CC
    Int J Artif Organs; 1998 Apr; 21(4):196-200. PubMed ID: 9649059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of unfractionated and low molecular weight heparins on diamine oxidase release.
    Biebl M; Klocker J; Perkmann R; Mühlthaler H; Kolbitsch C; Fraedrich G; Schwelberger HG
    Inflamm Res; 2003 Apr; 52 Suppl 1():S63-4. PubMed ID: 12755413
    [No Abstract]   [Full Text] [Related]  

  • 27. The effects of danaparoid, dalteparin and heparin on tissue factor-induced experimental disseminated intravascular coagulation and bleeding time in the rat.
    Miyake Y; Yokota K; Fujishima Y; Sukamoto T
    Blood Coagul Fibrinolysis; 2001 Jul; 12(5):349-57. PubMed ID: 11505077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro anticoagulation monitoring of low-molecular-weight heparin.
    Wang JQ; Shi XB; Yang JG; Hu DY
    Chin Med J (Engl); 2009 May; 122(10):1199-202. PubMed ID: 19493471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of electronegativity and angiotensin-converting enzyme inhibition on the kinin-forming capacity of polyacrylonitrile dialysis membranes.
    Désormeaux A; Moreau ME; Lepage Y; Chanard J; Adam A
    Biomaterials; 2008 Mar; 29(9):1139-46. PubMed ID: 18078988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
    Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
    Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Very low doses of unfractionated heparin potentiate the anti-Xa activity of low molecular weight heparin (enoxaparin).
    Pèrez-Requejo JL; Lucena-Solano O; Pérez-García M; Santarelli MT
    Thromb Res; 1997 Feb; 85(3):259-65. PubMed ID: 9058500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antithrombin III-Binding Site Analysis of Low-Molecular-Weight Heparin Fractions.
    Chen Y; Zhao J; Yu Y; Liu X; Lin L; Zhang F; Linhardt RJ
    J Pharm Sci; 2018 May; 107(5):1290-1295. PubMed ID: 29339133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anticoagulant effects of low-molecular-weight heparins in healthy cats.
    Alwood AJ; Downend AB; Brooks MB; Slensky KA; Fox JA; Simpson SA; Waddell LS; Baumgardner JE; Otto CM
    J Vet Intern Med; 2007; 21(3):378-87. PubMed ID: 17552440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bifunctional Dalteparin/Enoxaparin coated nanosilver formulation to prevent bloodstream infections during hemodialysis.
    Meher MK; Poluri KM
    Carbohydr Polym; 2022 Sep; 291():119546. PubMed ID: 35698376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-molecular-weight heparins for the treatment of deep-vein thrombosis.
    Cziraky MJ; Spinler SA
    Clin Pharm; 1993 Dec; 12(12):892-9. PubMed ID: 8137606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Anticoagulation in hemodialysis with a single dose of low molecular weight heparin].
    Vukusich A; Avalos C; Orellana G; Cifuentes C; Rivas J; Calderón F
    Rev Med Chil; 1995 Jun; 123(6):735-41. PubMed ID: 8525227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AN69-ST membrane, a useful option in two cases of severe dialysis reactions.
    Cerqueira A; Martins PA; Carvalho BA; Vasconcelos MP
    Clin Nephrol; 2015 Feb; 83(2):100-3. PubMed ID: 25208312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-thrombotic efficacies of enoxaparin, dalteparin, and unfractionated heparin in venous thrombo-embolism.
    Morris TA; Marsh JJ; Konopka R; Pedersen CA; Chiles PG
    Thromb Res; 2000 Nov; 100(3):185-94. PubMed ID: 11108906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of a polyacrylonitrile membrane and a membrane made of regenerated cellulose on the plasma concentrations of erythropoietin during hemodialysis.
    Opatrný K; Krouzecký A; Wirth J; Vít L; Eiselt J
    Artif Organs; 1998 Oct; 22(10):816-20. PubMed ID: 9790077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers.
    Eriksson BI; Söderberg K; Widlund L; Wandeli B; Tengborn L; Risberg B
    Thromb Haemost; 1995 Mar; 73(3):398-401. PubMed ID: 7667822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.